Bolt Biotherapeutics (BOLT) Competitors $0.66 +0.02 (+3.13%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends BOLT vs. RGLS, AGEN, FBIO, SABS, CRIS, MTEM, AMGN, VRTX, GILD, and REGNShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Regulus Therapeutics (RGLS), Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Curis (CRIS), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Regulus Therapeutics Agenus Fortress Biotech SAB Biotherapeutics Curis Molecular Templates Amgen Vertex Pharmaceuticals Gilead Sciences Regeneron Pharmaceuticals Bolt Biotherapeutics (NASDAQ:BOLT) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability. Which has better earnings & valuation, BOLT or RGLS? Regulus Therapeutics has lower revenue, but higher earnings than Bolt Biotherapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$11.17M2.26-$69.20M-$1.74-0.38Regulus TherapeuticsN/AN/A-$30.04M-$1.26-1.18 Do analysts prefer BOLT or RGLS? Bolt Biotherapeutics currently has a consensus target price of $3.50, suggesting a potential upside of 431.51%. Regulus Therapeutics has a consensus target price of $10.80, suggesting a potential upside of 624.83%. Given Regulus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Regulus Therapeutics is more favorable than Bolt Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Regulus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is BOLT or RGLS more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -592.57%. Regulus Therapeutics' return on equity of -55.47% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt Biotherapeutics-592.57% -61.40% -43.95% Regulus Therapeutics N/A -55.47%-49.37% Does the media favor BOLT or RGLS? In the previous week, Regulus Therapeutics had 5 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 5 mentions for Regulus Therapeutics and 0 mentions for Bolt Biotherapeutics. Regulus Therapeutics' average media sentiment score of 0.44 beat Bolt Biotherapeutics' score of 0.00 indicating that Regulus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Bolt Biotherapeutics Neutral Regulus Therapeutics Neutral Does the MarketBeat Community prefer BOLT or RGLS? Regulus Therapeutics received 409 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 65.04% of users gave Bolt Biotherapeutics an outperform vote while only 63.75% of users gave Regulus Therapeutics an outperform vote. CompanyUnderperformOutperformBolt BiotherapeuticsOutperform Votes8065.04% Underperform Votes4334.96% Regulus TherapeuticsOutperform Votes48963.75% Underperform Votes27836.25% Do institutionals & insiders have more ownership in BOLT or RGLS? 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 30.9% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, BOLT or RGLS? Bolt Biotherapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. SummaryRegulus Therapeutics beats Bolt Biotherapeutics on 12 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.20M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.3810.05116.1015.23Price / Sales2.26400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book0.225.594.775.07Net Income-$69.20M$153.56M$119.06M$225.46M7 Day Performance-3.06%0.13%0.80%0.37%1 Month Performance1.90%15.23%5.65%3.57%1 Year Performance-33.52%41.14%36.75%29.43% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics2.703 of 5 stars$0.66+3.1%$3.50+431.5%-33.2%$25.20M$11.17M-0.38100Gap UpRGLSRegulus Therapeutics2.7068 of 5 stars$1.49+2.1%$10.80+624.8%+21.1%$97.55MN/A-1.1830Analyst ForecastNews CoverageGap UpAGENAgenus3.8143 of 5 stars$4.05-3.6%$10.50+159.3%-75.6%$87.36M$156.31M-0.36389Upcoming EarningsShort Interest ↑FBIOFortress Biotech2.8545 of 5 stars$1.90flat$13.00+584.2%+13.1%$43.34M$84.51M-0.59186High Trading VolumeSABSSAB Biotherapeutics2.6412 of 5 stars$3.88+19.0%$12.40+219.6%+288.0%$35.81M$2.24M0.00140Negative NewsHigh Trading VolumeCRISCuris3.0834 of 5 stars$4.18-2.3%$23.00+450.2%-11.3%$25.00M$10.02M-0.5149Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageMTEMMolecular Templates1.673 of 5 stars$0.46+2.2%N/A-90.8%$2.96M$57.31M-0.1762Negative NewsAMGNAmgen4.5912 of 5 stars$319.22-0.3%$333.50+4.5%+22.4%$171.53B$28.19B40.8726,700Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionVRTXVertex Pharmaceuticals3.4628 of 5 stars$471.12-1.0%$492.50+4.5%+27.6%$122.85B$9.87B-232.085,400Upcoming EarningsAnalyst ForecastGILDGilead Sciences4.9367 of 5 stars$89.51+0.8%$86.85-3.0%+11.6%$111.44B$27.81B109.1618,000Upcoming EarningsAnalyst ForecastREGNRegeneron Pharmaceuticals4.8472 of 5 stars$843.60+0.6%$1,090.24+29.2%+6.6%$93.00B$13.12B22.3413,450Analyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Regulus Therapeutics Alternatives Agenus Alternatives Fortress Biotech Alternatives SAB Biotherapeutics Alternatives Curis Alternatives Molecular Templates Alternatives Amgen Alternatives Vertex Pharmaceuticals Alternatives Gilead Sciences Alternatives Regeneron Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BOLT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
